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Introduction
One of the major treatment options for coronary heart disease is 
percutaneous coronary intervention, which includes percutaneous 
transluminal coronary angioplasty (PTCA) and coronary artery 
bypass graft surgery.1)2) However, PTCA results in a higher incidence 
of restenosis3); moreover, post-implantation, in-stent restenosis 
occurs in approximately 30%-50% of cases.4) Neointima formation, 
similar to scarring of the injured artery, eventually leads to potentially 
devastating effects such as a heart attack.5)6) Among the available 
strategies for preventing restenosis, the drug-eluting stent (DES) is 
widely used in clinical practice.7) The surface of the DES is loaded 
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with drugs such as sirolimus and paclitaxel, and the DES also acts 
as a scaffold to hold the dilated arterial segment.7)8) However, the 
DES has various drawbacks, such as lacking the ability to target 
drug delivery to the diseased region, resulting in reduced drug 
effects and cytotoxicity of the drugs on the DES. Apart from these 
difficulties, DESs are also susceptible to “late stent thrombosis”, a 
process or event in which the blood clots inside the stent generally 
occurs in ≥1 year post-stent implantation. Therefore, the present 
research focused on a gene therapy approach to improve stent 
angioplasty with gene-delivery stents. 
One of the most appealing ways to prevent restenosis is by gene 
therapy, in which the therapeutic gene is delivered into the vascular 
tissue. Current procedures use either intravenous injection or a 
balloon catheter to introduce genes and carriers to the blood vessel. 
However, in cardiovascular gene therapy, we have to overcome the 
obstacle of delivering the therapeutic gene specifically to the target 
site, rather than to the blood circulatory system. One promising 
solution for gene therapy in-stent is the use of endovascular 
stents, which can act both as the gene carrier and the scaffold 
for localized and prolonged delivery of therapeutic genes into the 
diseased blood vessel wall.9-11)
Several reports in the literature have described gene therapy 
approaches using naked plasmids, viral vectors, and non-viral 
nano-delivery systems.12-14) However, several recurring issues have 
led researchers to reconsider their use in human clinical trials. These 
issues include inefficient in vivo gene transfer, high cytotoxicity, 
strong inflammatory reactions, and the potential risk of viral 
deoxyribonucleic acid (DNA) integration to the host’s genome. 
Disulfide cross-linked low molecular polyethylenimine (ssPEI) 
is a biodegradable polymer for gene delivery.15) A previous study 
showed the efficient transfection property of ssPEI in A10 vascular 
smooth muscle cells (VSMCs) line.14) We utilized microRNA 145/
ssPEI nanoparticles (MSN) nanoparticles immobilized on the 
hyaluronic acid (HA)-coated stent to develop a safe and effective 
gene-eluting stent system in the treatment of restenosis. HA 
enhances the proliferation and migration of endothelial cells 
at a later stage,16) whereas microRNA 145 delivered from MSN 
nanoparticles can knock down the initial over-growth of VSMCs 
near the implanted stent.17)
MicroRNAs (miRNAs) are post-transcriptional regulators that 
decrease cell proliferation, survival, and metabolism. In particular, 
miRNA 145 (miR-145) is well-known for its potential to regulate 
VSMC proliferation17); hence, in our study we hypothesized that 
smooth muscle cell (SMC) proliferation is weakened or inhibited by 
the successful delivery of miR-145. In order to prove this concept, 
we designed a novel method to coat the stent surface with miR-
145, leading to the suppression of the over-growth of SMCs.
We evaluated the microRNA 145 nanoparticle (MSN)-immobilized 
HA-coated stent in the New Zealand white rabbit iliac artery 
restenosis model. We determined its potential efficacy in the 
suppression of c-Myc expression and the treatment of restenosis 
with the New Zealand white rabbit iliac artery restenosis model. 
Based on these previous findings and present research, we have 
designed a new nano-medicine layer-by-layer (LbL)-coated stent 
for highly efficient delivery of therapeutic genes by targeted gene 
delivery.
Materials and Methods
Materials
We purchased miR-145 from Genolution Pharmaceuticals (Seoul, 
Korea). We transformed plasmid gWiz-luciferase (Aldevron, USA) 
into the competent cells, Escherichia coli DH5α, using the heat shock 
method. gWiz-luciferase was then propagated in bacterial cultures 
grown in Luria-Bertani media (Becton and Dickinson company, 
Franklin Lakes, NJ, USA) containing 100 µg/mL of kanamycin 
(Biosesang Inc., Sungnam, Korea), and purified using a mini DNA-
spin kit (iNtRON Biotechnology, Seongnam, Korea). We purchased 
an antibody for c-Myc and green fluorescent protein (GFP) from 
Genolution Pharmaceuticals (Seoul, Korea). We obtained branched 
PEI-linked ssPEI from Pohang University of Science and Technology. 
We purchased HA from Lifecore Biomedical (Chaska, MN, USA). 
We purchased 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
from TCI (Tokyo, Japan). Finally, we purchased 3-hydroxytyramine 
hydrochloride and 2-(N-Morpholino) ethanesulfonic acid (MES) 
from Sigma Aldrich (St. Louis, MO, USA) and used them without 
further purification. 
Stable coating method of hyaluronic acid on the stent surface 
First, 3-hydroxytyramine hydrochloride (1400 mg), 1-Ethyl-
3-(3-dimethylaminopropyl) carbodiimide (450 mg), and 5 M of 
hydrochloric acid (100 μL) were added to a solution of HA (1000 
mg) in 0.1 M of MES (150 mL). The reaction was stirred at room 
temperature for 12 h. Additional 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (450 mg) was added to the solution at each time point 
(3 h and 6 h). The polymer obtained was dialyzed with the MWCO 
3500 membrane against 100 mM of NaCl solution for 2 days and 
double distilled water (DDW) for 2 days, followed by lyophilization. 
The conjugation rate of catechol was determined by ultraviolet-
visible spectroscopy at 280 nm using dopamine standard solutions. 
The results showed that approximately 4.2% of the carboxylic 
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acid groups in the HA chain were conjugated with dopamine.17) 
O2 plasma (10 mmHg for 10 min)-treated stents were immersed 
in the catechol-modified HA (HA-catechol) solution (2 mg/mL) at 
an acidic pH (pH<2) for 1 h and then incubated with 10 mM of Tris 
buffer (with a pH of 8.5) containing HA-catechol (2 mg/mL) for 10 
h. After incubation, the stents were washed thoroughly with DDW 
and stored at 4°C until used.
Determination of binding efficiency of microRNA-145 
with disulfide cross-linked low molecular polyethylenimine 
nanoparticles from hyaluronic acid-coated stent surface 
The YOYO1-labeled plasmid-miR-145 (1 μg) complexed with either 
ssPEI or branched polyethylenimine (bPEI) was prepared at 10 and 20 
of nitrogen to phosphate (N/P) ratios for immobilization on an HA-
coated stent surface. After 15 min of incubation, complexes were then 
immobilized on the HA-coated stent surface and incubated for 24 h 
at room temperature. Successful immobilization efficiency of miR-
145 nanoparticles from the HA-coated stent surface was measured 
by fluorescent microscopy and ultra violet (UV)-spectrometer after 
supernatant samples were collected. 
Cell attachment on the surface of a hyaluronic acid-coated 
stent
For the cell attachment study, an HA-coated stent was placed 
into the 24-well plate and rinsed with 70% ethanol for sterilization. 
After drying, the miR-145 with ssPEI nanoparticles was immobilized 
on the HA-coated stent surface. The A10 VSMCs were seeded on 
the surface of the HA-coated stent at a density of 5.0×104 cells/
cm2 in Dulbecco’s modified eagle medium (DMEM) medium with 
supplementation of antibiotics and 10% Fetal Bovine Serum (FBS). 
To image the tissues grown on the stent surfaces, samples were 
fixed with 2.5% glutaraldehyde for 2 h before they underwent serial 
dehydration with increasing concentrations of ethanol (40, 50, 60, 
70, 80, 90, and 100%) in water for 10 min. After dehydration, the 
samples were dried overnight and sputter-coated using gold prior 
to observation under scanning electron microscopy.
Cell viability on microRNA-145 nanoparticle-immobilized 
hyaluronic acid-coated stent surface
The cellular viability of miR-145 nanoparticles with A10 cells 
was analyzed through MTS assay. miR-145 nanoparticles were 
immobilized on the HA-coated surface and incubated at room 
temperature for 24 h. After incubation, A10 cells were seeded at a 
density of 5×104 cells/cm2 and incubated at 37°C in a humidified 
atmosphere of 5% CO2. The cells were then washed with phosphate 
buffered saline (PBS) and 100 µL DMEM containing 10% FBS and 1% 
penicillin. The viability of the cell population was analyzed using an 
MTS assay (Promega, Madison, WI, USA). 
Measurement of c-Myc and green fluorescent protein  
expression at protein level by western blot
The A10 cells transfected with miR-145 (1 μg) were lysed after 
24 h, and protein was extracted using PRO-PREPTM (iNtRON 
Biotechnology, Seongnam, Korea). Total protein was quantified by 
a bicinchoninic acid protein assay kit (Invitrogen, Waltham, MA, 
USA). For western blot, equal amounts of protein were separated 
on sodium dodecyl sulfonate-polyacrylamide gel electrophoresis, 
transferred onto a nitrocellulose membrane, blocked, and incubated 
for 1 h with anti-c-Myc and anti-GFP antibodies. After washing, the 
membrane was incubated with a horseradish peroxidase-labeled 
secondary antibody. The bands were analyzed using a luminescent 
image analyzer (LAS-3000, Fujifilm, Tokyo, Japan). 
Animal preparation and stent implantation 
The animal studies were performed according to an experimental 
protocol approved by the Institutional Animal Care and Use 
Committee Ethics Committee of Chonnam National University 
Medical School and Chonnam National University Hospital (CNU 
IACUC-H-2011-5). Experiments were performed on New Zealand 
white rabbits (3.5 kg average weight; obtained from Damool 
Science, Daejeon, Korea). In vivo implantation and tissue harvesting 
procedures are described in the previous study.16) Briefly, the 
stents were implanted using fluoroscopic imaging (Philips, BV-
Pulsera, Eindhoven, Netherlands) under sterile conditions. Rabbits 
were anesthetized with a mixture of xylazine (2.2 mg/kg) and 
ketamine (22 mg/kg) prior to the experiment. A heating pad was 
used to maintain the body temperature, and the animals received 
supplemental oxygen continuously via an oxygen mask. Lidocaine 
solution (2%) was subcutaneously administered at the cut-down 
site. An incision was made above the right carotid artery, and the 
vessel was dissected free. A Radifocus® introducer with a 4-fr 
introducer sheath (Terumo Co., Tokyo, Japan), pre-loaded with a 
guide wire, was then inserted into the vessel and advanced from 
the carotid artery into the distal descending aorta. The guide wire 
was then advanced to the proximal portion of the iliac artery. The 
stent was deployed to a pressure of 12 atm to achieve a stent-to-
artery-size ratio range of 1.1–1.2:1.7. The bare metal stent (BMS) 
(3.0x9x18 mm, Co-Cr Alloy), the HA-coated stent, and MSNs/HA-
immobilized stent were implanted in the left or right iliac arteries 
alternatively in rabbits. After the stent deployment, intravenous 
heparin (100 U/kg) was administered immediately. The introducer 
sheath was removed after successful stent deployment verified by 
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angiography. After the procedure was completed, the rabbits were 
allowed to recover from anesthesia. Follow-up was performed 4 
weeks post-implantation to observe sequential alteration. The 
animals underwent follow-up angiography in the same views as 
initially performed, and they were subsequently sacrificed. 
Measurement of post-angioplasty restenosis by micro-com-
puted tomography imaging
The implanted stents were retrieved and stored in formaldehyde 
solution. The stents were placed in a V-shaped opening in clay, 
which had been prepared earlier in a 1.5 mL microcentrifuge tube. 
Stents had to be fixed firmly so that there would be no movement 
of the stent inside the microcentrifuge tube while imaging as 
performed. Omnihexol (Korea United Pharm Co., Seoul, Korea) was 
used as the contrast agent. A 5-mL syringe was used to inject the 
contrast agent (1 mL) through the opening at the center of the 
stents. The stents were incubated with contrast agent overnight 
and subjected to micro-computed tomography (CT) imaging. 
In vivo histological assessment of neo-intimal hyperplasia 
suppression 
The part of iliac arteries surrounding the stent was carefully 
removed and processed for histological analysis. The status of 
neointimal hyperplasia after the BMS, HA-coated stent, and MSNs/
HA-immobilized stent implantations was evaluated by histological 
analysis. The stents obtained at day 28 post-implantation were 
embedded in Glycol methacrylate blocks. Sections were cut with a 
diamond wafer mounted by IsoMet® Low Speed Saw (Buehler, USA). 
The sections were stained with H&E for histological analysis. The 
neointimal area was measured by tracing the internal elastic lamina 
(IEL) and the lumen area (LA). Mean IEL and LA were calculated 
using an imaging analysis system. The neointima area (NA) was 
calculated as follows: NA=IEL-LA. 
Statistical analysis
Statistical analysis was performed with the aid of commercially 
available software (SPSS Version 15; Chicago, IL, USA). The data 
were presented as mean value±standard deviation. Unpaired 
Student’s t-test was used for the comparison of the 3 stent groups. 
A value of p＜0.05 was considered statistically significant.
Results
Immobilization study of microRNA-145 nanoparticles on 
hyaluronic acid-coated stent surface
In order to visualize the immobilization of the nanoparticles 
over the HA-coated stent surface, the miR-145-plasmid was 
labeled with YOYO1 fluorescent dye. The YOYO1-labeled miR-145 
was incubated with ssPEI to form the complex. The complex was 
then coated over the HA-coated surface. After 24 h of incubation, 
efficient immobilization of the complex on the HA-coated stent 
surface was confirmed with fluorescent microscopy (Fig. 1). The 
complexes were distributed uniformly over the stent, which is 
evident from the green color signal from the YOYO1-labelled miR-
145 complexed with ssPEI. The negatively charged HA coating over 
Fig. 1. (A) Fluorescent microscopic image of YOYO1-labeled MSNs immobilized on the HA-coated stent surfaces. (B) The binding efficiency of YOYO1-
labeled MSN on an HA-coated stent surface. YOYO1-labeled miR-145 was complexed with ssPEI at N/P ratios of 10 and 20 and was then immobilized on 
the HA-coated stent surface. The unbound miR-145 was measured by a UV spectrophotometer. HA: hyaluronic acid, MSN: microRNA 145/disulfide cross-
linked low molecular polyethylenimine nanoparticles, ssPEI: disulfide cross-linked low molecular polyethylenimine, N/P: nitrogen to phosphate, miR: 
microribonucleic acid, UV: ultra violet.
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the stent facilitates ionic interaction with the positively charged 
miR-145 nanoparticles.
The YOYO1-labeled miR-145 was used to quantitate the 
percentage of immobilization over the stent. The YOYO1-labeled 
miR-145 was incubated with ssPEI at 10 of N/P ratios to form the 
fluorescent miR-145 nanoparticles. After complex formation, they 
were immobilized over the HA-coated stent surface and placed 
in a plate with PBS buffer. After 24 h of incubation, the solution 
was collected and the absorbance was measured. The supernatant 
solution was transferred to UV-transparent cuvettes, and the 
absorbance was measured at 490 nm using a UV spectrophotometer. 
More than 80% of the MSNs were bound over the HA-coated 
surface, and the binding efficiency of the ASNs on the HA-coated 
surface was not affected significantly (Fig. 1).
Cell attachment studies on microRNA-145/hyaluronic acid-
coated stents 
A10 VSMC lines were used to study cell attachment on miR-145/
HA-coated stents. We found that a larger number of cells were 
attached to the surface of the stent, indicating efficient binding of 
the cells to the stent surface, as illustrated in Fig. 2. Furthermore, 
the cells were uniformly spread over the stent, thereby aiding in the 
cellular uptake of the miR-145 nanoparticles as illustrated in Fig. 3. 
Successful immobilization and delivery of miR-145 nanoparticles 
to the cells attached on the stent would prevent post-angioplasty 
side effects such as the migration and over-growth of the VSMCs.
Cell viability 
The plasmid luciferase was complexed with ssPEI and bPEI to 
test their cytotoxicity in A10 cells. An MTS assay was performed 
to evaluate the cytotoxicity of ssPEI with the carrier luciferase/
bPEI nanoparticles as a positive control. Varying concentrations of 
luciferase, 1 to 3 μg, were tested for viability. The luciferase/ssPEI 
nanoparticles showed above 90% cell viability, when compared with 
the control. The viability of luciferase/bPEI was only 60% (Fig. 4).
c-Myc protein and green fluorescent protein suppression in 
vascular smooth muscle cells mediated by microRNA-145 
nanoparticles
A10 VSMCs were seeded on the miR-145 nanoparticles-
immobilized and HA-coated stent surface. After 24 h of incubation, 
the cells were collected from the stent surface and further processed 
for western blotting. The total protein was isolated to evaluate the 
suppression of the c-Myc and GFP protein at the protein level, 
respectively. Western blot data indicated that c-Myc protein and 
GFP were reduced in miR-145/ssPEI nanoparticles-treated cells, as 
compared to the control carrier, miR-145/bPEI nanoparticle-treated 
A10 cells (Fig. 5).
 
Micro-computed tomography imaging of restenosis after 
angioplasty
Micro-CT imaging was conducted after removal of the implanted 
stents, to calculate the percentage of tissue deposition. A stent 
without HA coating was used as the control in comparison with the 
HA-coated stent and miR-145 nanoparticle-immobilized HA-coated 
stents. The in-stent restenosis (ISR) area over the stent surface was 
calculated according to the formula in Fig. 6. The ISR area over the 
bare metal stent was aggravated, as compared to the HA-coated 
Fig. 2. SEM images of VSMCs adhering on the MSN-immobilized HA stent surface after overnight culture. SEM: scanning electron microscopy, VSMCs: 
vascular smooth muscle cells, MSN: microRNA 145/disulfide cross-linked low molecular polyethylenimine nanoparticles, HA: hyaluronic acid.
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and miR-145 nanoparticle-immobilized HA-coated stents. In 
particular, the ISR area over the miR-145 nanoparticle-immobilized 
HA-coated stent was greatly reduced due to the suppression of 
the overgrowth of VSMCs adhering to the stent surface, which 
was mediated by ribonucleic acid (RNA) interference with miR-
145. When the cells attached over the miR-145 nanoparticle-
immobilized HA-coated stent, the miR-145 nanoparticle complex 
was efficiently internalized in cells and the miR-145 expression in 
VSMCs was suppressed, leading to cell death (Fig. 6).
Histopathological analysis of neo-intimal suppression 
According to histopathological analysis, in-stent neointima is 
the interval between the internal elastic lamina and the lumen 
boundaries, as seen in vessel cross sections. To assess the suppressive 
effect of the MSN/HA-immobilized stents on restenosis post-
angioplasty, the neo-intimal-to-medial layer thickness ratio was 
calculated and compared to the BMS and HA-coated stent-treated 
groups (n=4/group). Arteries were stained with H&E. Fig. 7 showed 
representative images from each of the groups at 4×magnification. 
At 4 weeks post-implantation after the injury, the lumen area after 
4 weeks was 1.8±0.44, 3.0±0.15, and 4.1±0.06 for the BMS, HA-
coated stent, and MSN/HA-immobilized stent groups, respectively. 
Pathologic areas of neointimal for the BMS, HA-coated stent, and 
MSN/HA-immobilized stent groups were 2.9±0.44, 0.67±0.15, and 
0.37±0.06, respectively, and the differences among the groups 
were statistically significant (p=0.03 by analysis of variance). These 
results indicated that MSN/HA-immobilized stents mediated the 
suppression of neo-intimal hyperplasia (Fig. 7).
Discussion
Cytotoxic drugs or Cytostatics that inhibit SMC growth in 
the lumen, are used for clinically approved restenosis inhibition 
Fig. 3. The uptake of YOYO1-labeled microRNA-145/ssPEI from the HA stent was measured by confocal microscopy from 1 to 12 hours. miR: microRNA, ssPEI: 
disulfide cross-linked low molecular polyethylenimine, HA: hyaluronic acid.
Control 6 hr1 hr 12 hr
Fig. 4. The cell viability of VSMCs cultured on a luciferase/ssPEI nanoparticle-immobilized, HA stent surface. Different amounts of plasmid-luciferase (1-3 
μg) were complexed with ssPEI at a fixed N/P ratio of 10 to 30 and immobilized on the HA-coated surface. The cellular viability of VSMCs on the surface 
was measured using MTS assay (Promega, Madison, WI, USA).  VSMCs: vascular smooth muscle cells, ssPEI: disulfide cross-linked low molecular 
polyethylenimine, HA: hyaluronic acid, N/P: nitrogen to phosphate.
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therapies. Stents eluting these drugs are effective in cell proliferation 
inhibition,18) but they do not promote re-endothelilization of the 
vessel, which is crucial in the long-term treatment of restenosis.19)20) 
Despite the commercial availability of DESs, their safety in 
translation medicine is compromised due to the drug toxicity, delayed 
endothelization that leads to late thrombosis, and suboptimal 
polymer biocompatibility. One of the proposed solutions for the 
problems associated with DES is the gene eluting stents. The gene 
eluting stents with the aid of nanotechnology could easily prevent 
restenosis and late thrombosis by increasing the capacity of re-
endothelization.21)22)
Nanoparticles carrying genes that are coated on endovascular 
stents represents a novel gene delivery system, but currently 
available gene-coated stents lack safety and specific delivery to 
target cells without loss in the circulatory system. Moreover, uniform 
coating of stents with target genes and their effective delivery to 
the surrounding SMCs from the stent surface still remains a 
challenging task.
In terms of gene delivery carriers, viral gene carriers possess high 
transfection efficiency, but possess potential toxicity due to their 
cellular mechanism. To overcome this limitation, we focused on 
non-viral carriers. A cationic polymer i.e., branched PEI that forms 
a polyplex with nucleic acid and releases them intracellularly was 
used in this study.23) The higher transfection efficiency of branched 
PEI is similar to that of viral carriers. However, cytotoxicity was 
observed due to its non-degrading nature and higher charge 
density. For increasing the degradability, a disulfide bond that is 
stable in the oxidative extracellular environment, but reduced and 
degraded in the intracellular environment, was introduced in the 
PEI.24) In our study, dopamine-conjugated HA was stably coated on 
the stent surface, followed by the immobilization of MSNs on the 
HA surface of the stent. This was accomplished due to the fact that 
HA-linked dopamine forms a strong bond with various inorganic/
organic surfaces. One of the major advantage of HA coated 
stent is that it promotes re-endothelization with no significant 
inflammation25)26) and is furthermore a natural polymer that is 
highly biocompatible, non-immunogenic and easily degradable. 
One of the major problems of DESs in the post-surgery period is 
the toxicity arising from the polymer still attached to the surface of 
the stent; however, in our system, this problem was eliminated by 
the use of HA as the coating material. After the release of the micro 
RNA 145, HA coated on the surface of the stent would promote 
Fig. 5. Confirmation of miR-145 downstream pathway protein (c-Myc) and miR-145-GFP expression silencing after miR-145 treatments using ssPEI and 
bPEI carrier. Suppression of miR-145-GFP and downstream signaling proteins after the delivery of miR-145-GFP. The protein level was measured using 
western blotting. miR: microRNA, GFP: green fluorescent protein, ssPEI: disulfide cross-linked low molecular polyethylenimine, bPEI: branched 
polyethylenimine.
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re-endothelization and self-degrade inside the body. The results 
showed that microRNA 145 released from an MSN/HA immobilized 
stent surface was capable of reducing SMC proliferation due to the 
suppression of the c-Myc and other proteins in the microRNA 145 
Fig. 6. Observation of post-angioplasty restenosis by micro-CT imaging. In MSN/HA-immobilized and HA-coated stents, a thin vascular overgrowth of cells 
was observed, and the stent linings were visible (n=3). BMS: bare metal stent, miR: microRNA, ISR: in-stent restenosis, CT: computed tomography, MSN: 
microRNA 145/disulfide cross-linked low molecular polyethylenimine nanoparticles HA: hyaluronic acid.
Fig. 7. Measurement of neointima by hematoxylin & eosin (H&E) staining. The iliac arteries were harvested 4 weeks after stent implantation, fixed with 
paraformaldehyde, embedded in Glycol methacrylate, and stained with hematoxylin & eosin (H&E) staining. The upper panel shows representative arteries 
from the BMS and HA-coated stent, and MSN/HA-immobilized stent groups. BMS: bare metal stent, HA: hyaluronic acid, miR: microRNA, MSN: microRNA 
145/disulfide cross-linked low molecular polyethylenimine nanoparticles.
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signal transduction cascades. The reduction in SMC proliferation on 
the MSN/HA-immobilized stent surface was confirmed in vitro, and 
MSN/HA-immobilized stent implantation was observed in vivo with 
micro CT imaging in the region near the MSN/HA-immobilized stent 
surface. The tissue near the stent-implanted area was subjected 
to histological analysis for neo-intimal hyperplasia. In our study, 
the enzymatic degradation of HA in the blood stream occurred 
slowly after a faster release of MSNs to neighboring SMCs. The 
mechanistic and functional studies of an MSN/HA immobilized 
stent are currently underway in a cardiac infarction model and will 
be reported elsewhere.
The micro CT imaging of the stent-implanted area showed 
reduced ISR rate over the MSN/HA-immobilized stent region in 
comparison with the HA-coated stent and BMS regions. As the 
restenosis rate was reduced, the neo-intimal hyperplasia formation 
was analyzed histologically. In the MSN/HA-immobilized stent 
region, suppression of neo-intimal hyperplasia was observed, 
whereas, in the HA-coated stent and BMS regions there was 
little or no suppression of neo-intimal hyperplasia. The MSN/HA-
immobilized stents promoted re-endothelialization, which is the 
main drawback of DES usage.
In conclusion, we successfully demonstrated the coating of 
a biodegradable ssPEI carrier with microRNA 145 nanoparticles 
on the surface of HA-coated stents. Post-implantation studies 
were successfully in the rabbit restenosis model, and achieved 
the effective knock-down of the microRNA 145 and downstream 
protein c-Myc by microRNA 145, which retarded the undesired 
growth of VSMCs near the stents, thereby preventing restenosis.
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